FDA allows expanded use of Takeda's Velcade

06/23/2008 | Bloomberg

Takeda Pharmaceutical Co. Ltd. has obtained FDA clearance to market Velcade -- acquired through its $8.8 billion takeover of Millennium Pharmaceuticals in May -- as an initial treatment for patients with multiple myeloma. The additional approval is based on study results showing that Velcade helped 35% of people newly diagnosed with the blood cancer experience remission.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX